Overview

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Status:
Withdrawn

Trial end date:
2021-08-02

Target enrollment:

Participant gender:

Summary

This study is a phase II, multi-centre, open label study in patients with advanced ovarian cancer. The treatment being tested is Pamiparib, with daily dosing. All patients enrolled to the study will receive treatment with pamiparib. Patients will be selected for entry into the study based on the molecular signature of their cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Australia New Zealand Gynaecological Oncology Group

Collaborator:

BeiGene